About Epstein-Barr Virus (EBV) Glycoprotein gp350 Recombinant Protein

Epstein-Barr virus (EBV) is an enveloped double-stranded DNA virus belonging to the genus Lymphocryptovirus in the family Herpesviridae. Glycoprotein gp350 (gp350/220) is the most abundant envelope glycoprotein on the EBV surface and mediates the initial attachment of the virus to B lymphocytes by binding the complement receptor CR2 (CD21). This interaction initiates viral entry and facilitates subsequent membrane fusion mediated by other viral glycoproteins. Because gp350 is the primary target of virus-neutralizing antibodies, it has become one of the most extensively studied antigens for EBV vaccine development, antibody discovery, and serological assay development.

eEnzyme's EBV Glycoprotein gp350 Recombinant Protein is produced for research use and is suitable for antibody screening, receptor-binding studies, ELISA development, Western blotting, epitope mapping, structural characterization, and EBV vaccine research. This recombinant protein provides a valuable reagent for investigating EBV-host interactions, immune responses, and the development of diagnostics and antiviral therapeutics.

Applications

Biological Significance of EBV Glycoprotein gp350

EBV gp350 is the principal viral attachment protein responsible for recognizing CD21 (CR2) on B lymphocytes, making it a critical determinant of EBV infection. As the dominant surface antigen and the major target of neutralizing antibodies, gp350 has served as the basis for numerous vaccine candidates and therapeutic antibody studies. The EBV Glycoprotein gp350 Recombinant Protein provides a valuable research tool for studies of EBV biology, receptor interactions, immune responses, vaccine development, and diagnostic assay development.